SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes
Sellas Life Sciences Group (SLS) shares rose in premarket trading after CEO Angelos Stergiou said GPS in its AML Phase 3 Regal trial has a “very good chance” to match or beat earlier survival results. Regal reached 78 events as of May 11, with two events left before final analysis. Company targets median overall survival of 12.6 months vs 8.1 months.
How this was made
The 30-second read
Why it matters
Management commentary increases perceived probability of success and narrows the timeline to the final event threshold, which can drive trading volatility in small-cap biotech ahead of topline.
Market read
Traders are likely to reprice near-term odds for GPS success based on CEO’s “very good chance” comment and the trial’s proximity to the 80th event, with topline expected weeks after.
What to watch
Event timing delays can cut both ways, and the article does not provide updated efficacy numbers beyond prior phase II context, leaving uncertainty around the magnitude of any survival benefit.
Background
Sellas is running the Phase 3 Regal trial of Galinpepimut-S (GPS) in AML patients in second remission after salvage therapy, with final analysis tied to reaching 80 events.
Ticker impact
Sellas shares jumped premarket after CEO said GPS has a “very good chance” to match or beat earlier survival data as Regal nears final readout.
Likely supports continued premarket/near-term momentum, but remains event-risk until the final event threshold and data cleaning are complete.
The article provides a fresh CEO quote at a named forum plus specific trial progress (78 events as of May 11, two events remaining) and timing guidance (weeks after 80th event).
Market effects
Reinforces sentiment for AML immunotherapy/maintenance strategies and for CDK9 inhibitor read-throughs in high-risk, venetoclax-resistant settings.
No clear regional spillover beyond US small-cap biotech risk appetite.
Limited, as the catalyst is company-specific clinical timing and survival readout expectations.
Counterpoint
CEO optimism may be narrative rather than new efficacy data; the trial is still blinded and only two events remain, so outcomes could still disappoint.
Key entities
- companySellas Life Sciences Group
Subject of the article; GPS Phase 3 Regal trial is nearing its final event threshold, and CEO provided updated optimism and timing expectations.
- drugGalinpepimut-S (GPS)
Sellas’ AML immunotherapy in the Regal Phase 3 trial; CEO suggested it could mimic or outperform earlier survival outcomes.
- clinical_trialRegal Phase 3 trial
Randomized Phase 3 study comparing GPS versus standard treatment, with 78 events reached as of May 11 and two events remaining to reach 80.
- drugSLS009
Sellas’ Phase 2 CDK9 inhibitor in venetoclax-resistant AML, including studies in TP53 and ASXL1 mutation populations.
